Clinical Trials Logo

Fever clinical trials

View clinical trials related to Fever.

Filter by:

NCT ID: NCT03768869 Active, not recruiting - Fever Clinical Trials

Fever and Neutropenia in Pediatric Oncology Patients

Start date: February 2006
Phase: Phase 3
Study type: Interventional

It is possible to distinguish between pediatric oncology patients who are at high or low risk for serious infection during periods of fever and treatment related neutropenia based on clinical parameters. Patients with low risk can be safely treated as outpatients primarily using oral antibiotics. It is possible to improve methods of risk stratification through the addition of genomic and proteomic factors.

NCT ID: NCT03765931 Completed - Fever Clinical Trials

Comparative Efficacy of Single-dose Doxycycline Versus Standard 5- Day Amoxicillin Treatment

Start date: July 2016
Phase: Phase 4
Study type: Interventional

Abstract: Background The current practice in Senegal is to use broad-spectrum antibiotics including amoxicillin and/or cotrimoxazole in case of non-malarial fevers. First-line treatment with doxycycline has cured such patients. The investgators aimed to determine the efficacy of a single dose of doxycycline compared to a 5-day amoxicillin course for the treatment of fever.

NCT ID: NCT03758157 Completed - Fever Clinical Trials

Clinical Accuracy of the welloStationX

Start date: October 15, 2018
Phase: N/A
Study type: Interventional

This study evaluates the clinical accuracy of the welloStationX, an automated non-touch self-service electronic thermometer using an infrared sensor of the surface of the forehead to screen for fever.

NCT ID: NCT03757858 Recruiting - Cancer Clinical Trials

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Start date: March 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

It is a non-randomized pilot study.The allocation will be determined by patients or their immediate family members who were cooperative with physician's interpretations on the disease progression and updated information of cutting of edge treatment, the financial affordability, availability of treatment plans, possible tolerance or risks etc.The purpose of this study is to investigate the clinical efficacy and toxicity of autologous cellular immunotherapy combined with hyperthermia in abdominal and pelvic malignancies or metastases patients. Furthermore, to characterize response to different regimens,the investigators intent to explore the predictive and prognostic biomarker, as well as the changes in immune repertoire.

NCT ID: NCT03749850 Not yet recruiting - Breast Cancer Clinical Trials

Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer

i-GO
Start date: January 2019
Phase: Phase 1
Study type: Interventional

In this phase I feasibility study, the investigators evaluate the combination of lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox) with local hyperthermia and cyclophosphamide (C), for the local treatment of the primary breast tumour in patients with metastatic breast cancer. When heated to 40-43 degrees Celsius (ºC), LTLD releases a very high concentration of doxorubicin locally within seconds. Hyperthermia of the primary tumour will be induced by Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) on a dedicated Sonalleve MR-HIFU breast system. The investigators hypothesize that by substituting doxorubicin (A) in the AC-chemotherapy regimen for the combination of LTLD and MR-HIFU induced hyperthermia, optimal local tumour control can be achieved without compromising systemic toxicity or efficacy. This will be the first study to evaluate LTLD with MR-HIFU hyperthermia in breast cancer patients.

NCT ID: NCT03747315 Not yet recruiting - Clinical trials for Familial Mediterranean Fever

A Diagnostic Test for Familial Mediterranean Fever

DEPIST-FMF
Start date: January 1, 2019
Phase:
Study type: Observational

Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease (prevalence: 1-5 / 10,000 inhabitants). It is due to mutations of the MEFV gene, encoding variants of the Pyrin inflammasome. Inflammasomes are protein complexes of innate immunity producing pro-inflammatory cytokines (interleukin-1β). In vitro, preliminary results demonstrated that activation of the Pyrin inflammasome (measured by interleukin-1β concentration) by kinase inhibitors is significantly increased in FMF patients compared to subjects with a similar clinical picture, and healthy controls. In addition, a measure of cell death yielded significant results in differentiating patients from controls. The investigators hypothesize that this fast and simple functional test can serve as a diagnostic tool for FMF.

NCT ID: NCT03740646 Not yet recruiting - Fever Clinical Trials

Pneumocystis Primary Infection in Non-immunosuppressed Infants

CAPRI-PC
Start date: November 2018
Phase:
Study type: Observational

To determine the prevalence of P. jirovecii in nasopharyngeal aspirations of neonates and infants hospitalized for symptomatic respiratory infection.

NCT ID: NCT03740464 Recruiting - Clinical trials for Epithelial Ovarian Cancer

Long-acting G-CSF for Febrile Neutropenia

Start date: November 10, 2018
Phase: Phase 3
Study type: Interventional

This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer. Patients are randomized into study group and control group. In study group, patients accept long-acting G-CSF 48 hours from the chemotherapy. While the control group accept regular treatment rather than long-acting G-CSF. The primary end is the incidence of FN in every course of chemotherapy. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.

NCT ID: NCT03725618 Not yet recruiting - Yellow Fever Clinical Trials

Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old

Start date: November 2018
Phase: Phase 4
Study type: Interventional

A randomized clinical trial comparing fractional dose Yellow Fever vaccination to the full dose among children aged 9-23 months in Uganda. Children will have immune response assessed at baseline, 4 weeks, and 12 months after vaccination. Enrolled participants will be randomized to one of three arms: A. One-fifth fractional dose (0.1 ml) administered subcutaneously B. One-half fractional dose (0.25 ml) administered subcutaneously C. Full dose (0.5 ml) administered subcutaneously

NCT ID: NCT03717610 Recruiting - Clinical trials for Ovarian Cancer Recurrent

Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer

Start date: October 4, 2018
Phase: Phase 3
Study type: Interventional

This is a feasibility single-center study to investigate the tolerability, toxicity, quality of life, morbidity, mortality of the HIPEC treatment following cytoreductive surgery for treatment of recurrent ovarian, peritoneal, and fallopian tube cancers.